Month: October 2022

On July 7, 2022, Huo, Changxin; Wang, Hexiang; Lv, Gang; Wang, Zhiwei; Liu, Huaqing published a patent.COA of Formula: C15H29N3O2 The title of the patent was Degradation of bruton’s tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use. And the patent contained the following:

Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof. The title compounds I [ring A and B = (independently) an aromatic ring comprising 0-3 heteroatoms selected from N, S and O as ring member(s); Z1-Z4 = (independently) N or CRz; L = (independently) a bond, alkylene, O, etc.; m, n and q = (independently) 0-4; t = 0-2; R1 and R2 = (independently) H, alkyl, cycloalkyl, etc.; R3, R5 and R6 = (independently) H, halo, alkyl, etc.; Rz = the bond between moiety and Linker-Degron moiety, H, halo, etc.; the Linker = a bond or a divalent linking group; and the Degron = E3 Ubiquitin ligase moiety] or pharmaceutically acceptable salts thereof, were prepared E.g., a multi-step synthesis of II, starting from 4-phenoxybenzaldehyde and 4-methylbenzenesulfonohydrazide, was described. Exemplified compounds I were evaluated for their activity as BTK degradation (data given). Pharmaceutical composition comprising compound I was disclosed. The experimental process involved the reaction of tert-Butyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate(cas: 1211568-27-2).COA of Formula: C15H29N3O2

The Article related to bifunctional compound preparation bruton’s tyrosine kinase btk degradation, targeted protein degrader btk e3 ubiquitin ligase bifunctional compound, btk inhibitor e3 ligase conjugation bifunctional compound preparation and other aspects.COA of Formula: C15H29N3O2

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On February 6, 2003, Stankovic, Slobodan; Mitov, Slobodan; Stanojevic, Caslav published a patent.Synthetic Route of 86393-32-0 The title of the patent was A process for synthesis of antibiotic fluoroquinolonic acid derivatives. And the patent contained the following:

A simple and convenient procedure for obtaining antibiotics of fluoroquinolonic derivatives of general formula (I; where R, R2 = H, C1-4 alkyl; R1 = C1-4 alkyl, cycloalkyl such as cyclopropyl), and/or salts and hydrates thereof, in particular ciprofloxacin and norfloxacin, and is developed by amination of piperazine or piperazine derivatives (II; R = same as above) with the 6-fluoro-7-chloro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid derivative of general formula (III; R1 , R2 = same as above) in an inert solvent of pharmacopoeic purity, at risen temperature The process is characterized in lower reaction temperature, atm. pressure reaction, tech. simplicity of the procedure of purification by conversion and isolation in the form of pharmaceutically acceptable salts, increased yields, reducing cost on the procedure for industrial use, as well as pharmacopoeic purity of the product, enabled their use as the antibiotics in human and veterinary medicine. Thus, a mixture of 49.25 g 7-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic acid, 72.25 g piperazine, and 250 cm3 of DMSO was heated for 1.5 to 2 h at 140°, cooled to 70°, treated with 985 cm3 distilled water, and then treated with 62.5 cm3 concentrated HCl with stirring and cooling. Formed suspension was filtered and the precipitate was rinsed with distilled water, suspended in water, dissolved by addition of 2 mol/dm3 HCl, treated with active charcoal, heated with stirring at 50°, and filtered. To the filtrate was added 2 mol/dm3 NaOH with stirring and cooling and the formed suspension was filtered. The precipitate was rinsed with distilled water, suspended in water with stirring, treated with 60 cm3 2 mol/dm3 HCl, heated for 30 min at 75-80°, and added to 1,750 cm3 absolute ethanol. The mixture was cooled to 0-5° and filtered, and the precipitate was rinsed three times with 30 cm3 absolute ethanol each time, and dried in vacuum drier at 80° to give 49.46 g ciprofloxacin hydrochloride monohydrate (1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-piperazinoquinoline-3-carboxylic acid hydrochloride monohydrate) as white crystals having m.p. 308-310° (decomposition) in 73% yield. The experimental process involved the reaction of 1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride hydrate(cas: 86393-32-0).Synthetic Route of 86393-32-0

The Article related to fluoroquinolonic acid preparation antibiotic, ciprofloxacin hydrochloride monohydrate preparation antibiotic, fluoropiperazinodihydrooxoquinolinecarboxylic acid preparation antibiotic, norfloxacin preparation antibiotic and other aspects.Synthetic Route of 86393-32-0

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 31, 2022, Szeto, Andy H.; Bucci, Tyler; Deal, Allison; Zhu, Anqi; Ahmad, Majd; Cass, Amanda S.; Sketch, Margaret R.; Kemper, Ryan; Zeidner, Joshua F.; Foster, Matthew C.; Muluneh, Benyam; Crona, Daniel J. published an article.Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia. And the article contained the following:

Tyrosine kinase inhibitors (TKIs) are the front-line therapy for chronic myeloid leukemia (CML), where phase 3 clin. trials have demonstrated their safety and efficacy. However, trial patients may not be representative of real-world patients (RWPs). To evaluate RWP clin. factors associated with effectiveness and safety in CML patients treated with TKIs. Patients with CML treated with at least 30 days of imatinib, dasatinib, nilotinib, or bosutinib between 2014 and 2018 were included. Patients were stratified into categories based on the number of factors that would have precluded enrollment into pivotal TKI phase 3 trials (0, 1, ≥2). End points included complete hematol. response (CHR), early mol. response (EMR), major mol. response (MMR), adverse event (AE)-induced dose decreases, treatment interruptions, and treatment discontinuations. Final analyses included 174 patients. Patients with ≥2 factors had a higher risk of dose decreases (relative risk = 1.54; 95% CI = 1.02-2.34; P = 0.02) and a shorter time to dose decrease (hazard ratio = 2.43; 95% CI = 1.23-4.97; P = 0.006) compared with patients with 0 factors. Significant differences were observed in CHR at 1 mo and MMR at 3 mo between patients with 0 and ≥2 factors (P = 0.03 and P = 0.04, resp.). Approx. 60% of our RWPs would have been excluded from the pivotal phase 3 TKI trials. These data suggest that RWPs require more precise dosing to achieve CML clin. milestones and to mitigate AEs, but findings should be validated prospectively. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to imatinib dasatinib anticancer agent chronic myeloid leukemia adult, adverse drug events, bosutinib, chronic myeloid leukemia, dasatinib, effectiveness, imatinib, nilotinib, real-world patients, tyrosine kinase inhibitors and other aspects.Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On March 2, 2021, Biswas, Debabrata; Ambalavanan, Poornima; Ravins, Miriam; Anand, Aparna; Sharma, Abhinay; Lim, Kimberly Xuan Zhen; Tan, Rachel Ying Min; Lim, Hwee Ying; Sol, Asaf; Bachrach, Gilad; Angeli, Veronique; Hanski, Emanuel published an article.Category: piperazines The title of the article was LL-37-mediated activation of host receptors is critical for defense against group A streptococcal infection. And the article contained the following:

Group A Streptococcus (GAS) causes diverse human diseases, including life-threatening soft-tissue infections. It is accepted that the human antimicrobial peptide LL-37 protects the host by killing GAS. Here, we show that GAS extracellular protease ScpC N-terminally cleaves LL-37 into two fragments of 8 and 29 amino acids, preserving its bactericidal activity. At sub-bactericidal concentrations, the cleavage inhibits LL-37-mediated neutrophil chemotaxis, shortens neutrophil lifespan, and eliminates P2X7 and EGF receptors ‘ activation. Mutations at the LL-37 cleavage site protect the peptide from ScpC-mediated splitting, maintaining all its functions. The mouse LL-37 ortholog CRAMP is neither cleaved by ScpC nor does it activate P2X7 or EGF receptors. Treating wild-type or CRAMP-null mice with sub-bactericidal concentrations of the non-cleavable LL-37 analogs promotes GAS clearance that is abolished by the administration of either P2X7 or EGF receptor antagonists. We demonstrate that LL-37-mediated activation of host receptors is critical for defense against GAS soft-tissue infections. The experimental process involved the reaction of N-((4-(4-Phenylpiperazin-1-yl)tetrahydro-2H-pyran-4-yl)methyl)-2-(phenylthio)nicotinamide(cas: 1428327-31-4).Category: piperazines

The Article related to host receptor ll37 activation defense streptococcal infection, cramp, egfr, gas, ll-37, p2x7r, group a streptococcus, host-defense peptides, innate immunity, murine models of human gas soft-tissue infections, neutrophils and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 25, 2000, Folkman, Moses J.; Ingber, Donald; Fujita, Takeshi published a patent.Application of 53788-12-8 The title of the patent was Preparation of O-substituted fumagillol derivatives with angiogenesis inhibitory activity. And the patent contained the following:

This invention relates to the preparation and use of O-substituted fumagillol derivatives of formula I [R1 = (substituted) 2-methyl-1-propenyl, (substituted) isobutyl; R2 = alkanoyl, aroyl, aromatic heterocycle-carbonyl, carbamoyl, alkyl, alkylsulfonyl, alkoxycarbonyl, etc.], or salts thereof preferably, O-(N-chloroacetylcarbamoyl)fumagillol, O-(N-chloroacetylcarbamoyl)dihydrofumagillol or O-(N-chloroacetylcarbamoyl)-6’b-hydroxyfumagillol, which have angiogenesis inhibitory activity, in the treatment and prevention of various diseases caused or advanced by abnormally hyperactive angiogenesis, especially various inflammatory diseases (rheumatism, psoriasis, etc.), diabetic retinopathy and cancer and other angiogenesis-dependent tumors, especially Kaposi’s sarcoma, breast cancer, colon cancer. Thus, II (AGM-1470) was prepared from fumagillol and chloroacetyl isocyanate in 71% yield. The T/C ratio of II in the B16 mouse melanoma model was 0.47 after 2 wk and 0.20 after 3 wk. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Application of 53788-12-8

The Article related to fumagillol derivative preparation angiogenesis inhibitor, kaposi sarcoma treatment fumagillol derivative preparation, breast cancer treatment fumagillol derivative preparation, antitumor fumagillol derivative preparation and other aspects.Application of 53788-12-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On April 30, 2020, Wenzel, Tim; Buech, Thomas; Urban, Nicole; Weirauch, Ulrike; Schierle, Katrin; Aigner, Achim; Schaefer, Michael; Kalwa, Hermann published an article.Computed Properties of 380843-75-4 The title of the article was Restoration of MARCK enhances chemosensitivity in cancer. And the article contained the following:

Increased ATP-binding-cassette (ABC) transporter activity is a major cause of chemotherapy resistance in cancer. The ABC transporter family member ABCB1 is often overexpressed in colorectal cancer (CRC). Phosphatidylinositol-4,5-bisphosphat (PI(4,5)P2)-dependent pathways are involved in the regulation of ABCB1 function. The protein Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) is a pivotal regulator of PI(4,5)P2 and inactivated in many CRC cancers via genetic deletion or hyperphosphorylation. Therefore, MARCKS may critically impact ABCB1. CRC samples as well as CRC cell lines were tested for a connection between MARCKS and ABCB1 via immunofluorescence and Western-blot anal. ABCB1 function was studied via calcein influx assay under treatment with known ABCB1 inhibitors (verapamil, tariquidar) as well as the kinase inhibitor bosutinib. ABCB1 internalization and MARCKS translocation was analyzed via confocal microscopy exploiting the endocytosis inhibitors chlorpromazine and dynasore. Abundance of PI(4,5)P2 was monitored by intramol. fluorescence resonance energy transfer (FRET). Reproductive cell survival was studied via colorimetric WST-1 and clonogenic assays in combination with exposure to the chemotherapeutics doxorubicin and 5-fuorouracil (5-FU). We found increased ABCB1 expression in MARCKS neg. CRC patient tumor samples and established CRC cell lines. Mechanistically, the reconstitution of MARCKS function via recombinant expression or the pharmacol. inhibition of MARCKS phosphorylation led to a substantial decrease in ABCB1 activity. In CRC cells, bosutinib treatment resulted in a MARCKS translocation from the cytosol to the plasma membrane, while simultaneously, ABCB1 was relocated to intracellular compartments. Inhibition of MARCKS phosphorylation via bosutinib rendered cells more sensitive to the chemotherapeutics doxorubicin and 5-FU. Cells devoid of MARCKS function showed incomplete ABCB1 internalization, leading to higher ABCB1 activity enhancing chemoresistance. Vice versa our data suggest the prevention of MARCKS inhibition by reversing hyperphosphorylation or genomic restoration after deletion as two promising approaches to overcome tumor cell resistance towards chemotherapeutic ABCB1 substrates. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Computed Properties of 380843-75-4

The Article related to cancer chemosensitivity marck abc, atp-binding-cassette (abc) transporter, chemotherapy resistance, colorectal cancer, myristoylated alanine-rich c-kinase substrate, p-glycoprotein 1, phosphatidylinositol-4,5-bisphosphat and other aspects.Computed Properties of 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On April 30, 2022, Kumar, Veerandra; Singh, Priyanka; Gupta, Sonu Kumar; Ali, Villayat; Verma, Malkhey published an article.Formula: C26H29Cl2N5O3 The title of the article was Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review. And the article contained the following:

A review. Imatinib, nilotinib, dasatinib, bosutinib, ponatinib, and asciminib are FDA-approved tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML), each of which has a specific pharmacol. profile. Asciminib has been recently (2021) approved for patients resistant to former TKIs, and because the binding site of this drug (the myristoyl pocket in the ABL1 kinase) is different from that of other TKIs (ATP-binding sites), it is, therefore, effective against T315I mutation of BCR-ABL oncoprotein. All TKIs have a different pharmacol. profile due to different chem. structures. Imatinib is the only TKI whose absorption depends on both influx (OCT1 and OATP1A2) and efflux (ABCB1 and ABCG2) transporters, whereas the others rely only on efflux transporters. The efflux of dasatinib is also regulated by ABCC4 and ABCC6 transporters. Nilotinib and ponatinib are transported passively, as no role of transporters has been found in their case. A phenomenon common to all in the metabolic aspect is that the CYP3A4 isoform of CYP450 primarily metabolizes TKIs. Not only does CYP3A4, flavin-containing monooxygenase 3 (FMO3), and uridine 5′-diphospho-glucuronosyltransferase (UGT) also metabolize dasatinib, and similarly, by glucuronidation process, asciminib gets metabolized by UGT enzymes (UGT1A3, UGT1A4, UGT2B7, and UGT2B17). Addnl., the side effects of TKIs are categorized as hematol. (thrombocytopenia, neutropenia, anemia, and cardiac dysfunction) and non-hematol. (diarrhea, nausea, vomiting, pleural effusion, and skin rash). However, few toxicities are drug-specific, like degradation of biomols. by ponatinib-glutathione (P-GSH) conjugates and clin. pancreatitis (dose-limited toxicity and manageable by dosage alterations) are related to ponatinib and asciminib, resp. This review focuses on the pharmacokinetics of approved TKIs related to CML therapy to comprehend their specificity, tolerability, and off-target effects, which could help clinicians to make a patient-specific selection of CML drugs by considering concomitant diseases and risk factors to the patients. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Formula: C26H29Cl2N5O3

The Article related to review tyrosine kinase inhibitor metabolism chronic myeloid leukemia therapy, atp-binding cassette (abc) transporters, bcr-abl oncoprotein, cytochrome p450 (cyp450), multidrug resistance, pharmacokinetics, t315i mutation and other aspects.Formula: C26H29Cl2N5O3

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 18, 1975, there was a patent about cycloaddition reaction.Recommanded Product: 53788-12-8 The title of the patent was p-Dithiino[2,3-c]pyrroles. And the patent contained the following:

Dithiinopyrroles I (R = OH, OMe, R1 = H; R = Me, R1 = H, Me, Cl, OMe; R = H, R1 = Cl, Me, OMe) were prepared by treating the 2-aminonaphthyridines with 5,6-dihydro-1,4-dithiin-2,3-dicarboxylic anhydride, chlorinating when R1 = OH, reducing the dithiinopyrroledione to the monohydroxy derivative, and treating the latter with chlorocarbonylpiperazines. II (R2 = Et, CHMe2, allyl, CH2CH2OH) were similarly prepared The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Recommanded Product: 53788-12-8

The Article related to dithiinopyrrolol piperazinecarboxylate naphthyridinyl pyridinyl, piperazinecarboxylate naphthyridinyldithiinopyrrolyl, pyridinyldithiinopyrrolyl piperazinecarboxylate, aminonaphthyridine dithiindicarboxylate condensation and other aspects.Recommanded Product: 53788-12-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On September 16, 2021, Ewin, Richard Andrew; Cox, Mark R.; Hot, Imelda; Bedore, Matthew W.; Respondek, Tomasz; Sheehan, Susan M.K. published a patent.Recommanded Product: 53788-12-8 The title of the patent was Preparation of heteroaryl azalide glycosides as immunomodulators. And the patent contained the following:

Defined herein are immunomodulating heteroaryl azalide glycosides I, stereoisomers thereof, and pharmaceutically acceptable salts thereof; wherein W is H, sugar residue; RingC is Ph, naphthyl, 5-6 membered monocyclic heteroaryl ring or 9-11 membered fused heteroaryl ring; R1 is substituted benzyl, CH2-heteroaryl; R2 is H, alkyl, acyl, substituted amide, alkylaryl, alkyl-heterocycle; R3 is alkyl, alkoxy, haloalkyl, haloalkoxy, alkyl-cycloalkyl, halogen, substituted amine, substituted amide, substituted sulfoxide, nitro, oxo, cyano, -C(O)H, acyl, carboxylate, oxo-carboxylate, OH, heterocyclic, heteroaryl; n is an integer 0-3; and pharmaceutically acceptable salts thereof; and compositions comprising said compounds Thus, heteroaryl azalide glycoside II was prepared The invention also includes methods for treating an inflammatory and/or immunol. disease or disorder in an animal by administering a therapeutically effective amount of compound, stereoisomer thereof, and a pharmaceutically acceptable salt thereof; or use of said compounds to prepare a medicament for treating an inflammatory and/or immunol. disease or disorder in an animal. The experimental process involved the reaction of 4-Ethyl-piperazine-1-carbonyl chloride(cas: 53788-12-8).Recommanded Product: 53788-12-8

The Article related to polonovski demethylation aminoglycoside preparation human antiinflammatory, il1 cd163 tnf nfkb azithromycin macrolide aminoglycoside preparation human, immunomodulating hetero aryl tlr4 toll like receptor antiinflammatory and other aspects.Recommanded Product: 53788-12-8

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Saydam, Guray; Ali, Ridvan; Demir, Ahmet Muzaffer; Eskazan, Ahmet Emre; Guvenc, Birol; Haznedaroglu, Ibrahim Celalettin; Ozcan, Mehmet Ali; Salim, Ozan; Sonmez, Mehmet; Tuglular, Ayse Tulin; Turgut, Mehmet; Unal, Ali; Aver, Birkan; Bozkurt, Sirac; Ozdengulsun, Begum; Ilhan, Osman published an article in 2022, the title of the article was The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.HPLC of Formula: 380843-75-4 And the article contains the following content:

A review. Tyrosine kinase inhibitors (TKIs) approved for chronic myeloid leukemia known to have similar efficacies but different safety profiles. Therefore, the choice of patient-specific treatments is driven by factors such as tolerability and adverse event profile of TKIs. This review article examines the most up-to-date data and provides practical recommendations for clin. approaches. Nilotinib and ponatinib should be avoided in patients with cardiovascular risk factors, dasatinib in patients with lung damage and bosutinib and nilotinib in patients with liver disease. Considering that certain comorbidities predispose some patients to developing severe adverse events when receiving TKIs, the first- and second-line treatment of chronic myeloid leukemia should be tailored to each patient’s individual condition. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).HPLC of Formula: 380843-75-4

The Article related to review chronic myeloid leukemia comorbidity tki nilotinib ponatinib dasatinib, adverse event, chronic myeloid leukemia, comorbidity, drug toxicity, interactions (drug–drug), safety, tolerability, tyrosine kinase inhibitor and other aspects.HPLC of Formula: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics